Comparable stake leader
TANG CAPITAL MANAGEMENT LLC
SEC ownership of PLIANT THERAPEUTICS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001746473.
Disclosed value leader
TANG CAPITAL MANAGEMENT LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- PLRX on Nasdaq
- Parsed ownership sources
-
13D/G and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
TANG CAPITAL MANAGEMENT LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
TANG CAPITAL MANAGEMENT LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001746473
- Issuer location
- South San Francisco, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of PLIANT THERAPEUTICS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TANG CAPITAL MANAGEMENT LLC
Disclosed value leader
TANG CAPITAL MANAGEMENT LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
Lead comparable stake: 9.6%
13D/G row: TANG CAPITAL MANAGEMENT LLC
Showing 1-8 of 50 holder rows.
Quick read
TANG CAPITAL MANAGEMENT LLC leads the comparable SEC ownership view at 9.6%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens TANG CAPITAL MANAGEMENT LLC's linked filing trail.
Comparable ownership
Top 5
TANG CAPITAL MANAGEMENT LLC
9.6%
ADAR1 Capital Management, LLC
8.9%
VANGUARD GROUP INC
4.9%
Redmile Group, LLC
4.8%
CITADEL ADVISORS LLC
3.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC |
13D/G
13F
Company
|
9.6%
|
$9,198,699
5,859,044 shares
|
$0 | 03 Mar 2025 |
| ADAR1 Capital Management, LLC |
13D/G
13F
Company
|
8.9%
|
$6,281,085
5,509,724 shares
|
$0 | 30 Jun 2026 |
| VANGUARD GROUP INC |
13D/G
The Vanguard Group
|
4.9%
|
$3,482,724
3,002,348 shares
|
$0 | 30 Jun 2025 |
| Redmile Group, LLC |
13D/G
13F
Company
|
4.8%
|
$4,545,900
2,895,478 shares
|
$0 | 31 Dec 2024 |
| CITADEL ADVISORS LLC |
13D/G
13F
Kenneth Griffin · Company
|
3.5%
|
$2,443,506
2,143,426 shares
|
-$1,024,526 | 30 Jun 2026 |
| BlackRock, Inc. |
13D/G
13F
Company
|
3.4%
|
$2,440,674
2,104,574 shares
|
$0 | 30 Jun 2025 |
| Woodline Partners LP |
13D/G
13F
Company
|
3.3%
|
$2,471,953
2,026,191 shares
|
-$3,023,924 | 31 Dec 2025 |
| MORGAN STANLEY |
13D/G
13F
Company
|
0.9%
|
$861,460
545,228 shares
|
-$5,043,529 | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$163,620.
Buys
$0
Insiders: 0
Sells
$163,620
Insiders: 4
Net
-$163,620
Shares: -127,828
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 127,828
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 127,828 | $0 | $163,620 | -$163,620 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 22 reporting-owner rows connected to PLIANT THERAPEUTICS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
22
Largest Forms 3/4/5 holder
Third Rock Ventures III, L.P.
Net 12M change
-$163,621
Latest report
09 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Third Rock Ventures III, L.P. | 10%+ Owner | $68,438,025 | Mixed | 29 Nov 2022 | ||
| Hans Hull | Chief Business Officer | $2,920,870 | Mixed | 23 Jan 2025 | ||
| Eric Lefebvre | Chief Medical Officer | $2,640,879 | Mixed | 23 Jan 2025 | ||
| Mike Ouimette | General Counsel & Corp. Sec'y | $1,160,287 | Mixed | 23 Jan 2025 | ||
| Bernard Coulie | President and CEO, Director | $1,146,535 | -$114,400 | -9.1% | Mixed | 17 Apr 2026 |
| Keith Lamont Cummings | Chief Financial Officer | $380,433 | -$30,723 | -7.5% | Filing P/S | 17 Apr 2026 |
| Steve E. Krognes | Director | $111,338 | Mixed | 11 Jun 2026 | ||
| Lily Cheung | Chief Human Resource Officer | $57,404 | -$9,644 | -14% | Filing P/S | 17 Apr 2026 |
| Curnutte John T. | Director | $55,669 | Mixed | 11 Jun 2026 | ||
| Thomas A. Mccourt | Director | $55,669 | Mixed | 11 Jun 2026 | ||
| Darren S. Cline | Director | $55,669 | Mixed | 11 Jun 2026 | ||
| Katharine Knobil | Director | $55,669 | Mixed | 05 Jun 2025 | ||
| Smital Shah | Director | $55,669 | Mixed | 13 Jun 2024 | ||
| Hoyoung Huh | Director | $55,669 | Mixed | 11 Jun 2026 | ||
| David E. I. Pyott | Director | $55,669 | Mixed | 05 Jun 2025 | ||
| Gayle A. Crowell | Director | $55,669 | Mixed | 11 Jun 2026 | ||
| Suzanne Louise Bruhn | Director | $55,669 | Mixed | 05 Jun 2025 | ||
| Minnie Kuo | Chief Operating Officer | $48,391 | -$8,854 | -15% | Filing P/S | 17 Apr 2026 |
| Neil Exter | Director | Mixed | 16 Jun 2022 | |||
| Charles J. Homcy | Director | Mixed | 29 Jun 2021 |
Recent insider transactions for PLIANT THERAPEUTICS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Robert Iannone | PLRX | Stock Option (Right to Buy) | Award | 60,000 | 60,000 | 09 Jul 2026 | Direct | |||
| Flavia Borellini | PLRX | Stock Option (Right to Buy) | Award | 60,000 | 60,000 | 09 Jul 2026 | Direct | |||
| Gayle A. Crowell | PLRX | Stock Option (Right to Buy) | Award | 70,000 | 70,000 | 11 Jun 2026 | Direct | |||
| Thomas A. Mccourt | PLRX | Stock Option (Right to Buy) | Award | 70,000 | 70,000 | 11 Jun 2026 | Direct | |||
| Steve E. Krognes | PLRX | Stock Option (Right to Buy) | Award | 70,000 | 70,000 | 11 Jun 2026 | Direct | |||
| Curnutte John T. | PLRX | Stock Option (Right to Buy) | Award | 70,000 | 70,000 | 11 Jun 2026 | Direct | |||
| Hoyoung Huh | PLRX | Stock Option (Right to Buy) | Award | 70,000 | 70,000 | 11 Jun 2026 | Direct | |||
| Darren S. Cline | PLRX | Stock Option (Right to Buy) | Award | 70,000 | 70,000 | 11 Jun 2026 | Direct | |||
| Minnie Kuo | PLRX | Stock Option (Right to Buy) | Award | 245,200 | 150,000 | 17 Apr 2026 | Direct | |||
| Minnie Kuo | PLRX | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -245,200 | 0 | 17 Apr 2026 | Direct | ||
| Keith Lamont Cummings | PLRX | Stock Option (Right to Buy) | Award | 592,495 | 124,000 | 17 Apr 2026 | Direct | |||
| Keith Lamont Cummings | PLRX | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -592,495 | 0 | 17 Apr 2026 | Direct | ||
| Bernard Coulie | PLRX | Stock Option (Right to Buy) | Award | 1,951,703 | 440,000 | 17 Apr 2026 | Direct | |||
| Bernard Coulie | PLRX | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -1,951,703 | 0 | 17 Apr 2026 | Direct | ||
| Lily Cheung | PLRX | Stock Option (Right to Buy) | Award | 226,750 | 123,000 | 17 Apr 2026 | Direct | |||
| Lily Cheung | PLRX | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -226,750 | 0 | 17 Apr 2026 | Direct | ||
| Keith Lamont Cummings | PLRX | Stock Option (Right to Buy) | Award | 400,000 | 400,000 | 22 Jan 2026 | Direct | |||
| Minnie Kuo | PLRX | Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 22 Jan 2026 | Direct | |||
| Lily Cheung | PLRX | Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 22 Jan 2026 | Direct | |||
| Bernard Coulie | PLRX | Stock Option (Right to Buy) | Award | 1,230,000 | 1,230,000 | 22 Jan 2026 | Direct | |||
| Keith Lamont Cummings | PLRX | Common Stock | Sale | -7.47% | $30,723 | $1.28 | -24,002 | 297,214 | 20 Jan 2026 | Direct |
| Lily Cheung | PLRX | Common Stock | Sale | -14.4% | $9,644 | $1.28 | -7,534 | 44,847 | 20 Jan 2026 | Direct |
| Bernard Coulie | PLRX | Common Stock | Sale | -15% | $114,400 | $1.28 | -89,375 | 505,601 | 20 Jan 2026 | Direct |
| Minnie Kuo | PLRX | Common Stock | Sale | -15.5% | $8,854 | $1.28 | -6,917 | 37,806 | 20 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.